• Arabic

  • Chinese (Simplified)

  • English

  • French

  • German

  • Italian

  • Japanese

  • Portuguese

  • Russian

  • Spanish

Contact Us

About

TELJANE

We were founded in July 2021 in Shanghai, China, with a focus on the R&D and industrialization of innovative medical devices for glucose management. Our core team is composed of leading experts from China and abroad, dedicated to advancing high-sensitivity and long-duration biosensor technologies that are at the forefront of the global industry.

  • 64+
    Partners
  • 9+
    Trademarks
  • 36+
    Patents
2021-2025

Milestones

  • 2021
    • Established laboratories in Shanghai, China and Silicon Valley, USA
  • 2022
    • Our self-developed biosensors reached performance benchmarks beyond those previously seen in the industry.
  • 2023
    • Core product prototype development completed.
    • First GMP-grade intelligent production line completed.
    • Successfully launched small-batch trial production.
  • 2024
    • Passed full regulatory approval and biosafety testing;
    • Achieved ISO 13485 and MDSAP dual certification;
    • Initiated clinical trials;
  • 2025
    • We began mass production, defining the future of glucose and metabolite monitoring.

    • With a MARD of just 8.2%, key clinical trials were completed, laying a strong foundation for global market entry.

    • Second smart factory launched,accelerating large-scale commercialization.

Global Service Network

Driven by technological innovation, Teljane upholds the vision of “Pursuing Excellence, Becoming a Leader in Glucose Management, and Benefiting Diabetic Patients Worldwide.”

Financing History

Stable operations and continuous investment are driving sustainable advancement, ensuring steady progress in product development, clinical validation, and market preparation.

1

2022 Angel Round

Investor: Xieli Capital 

  • Identified Teljane’s early potential in biosensing technology.
  • Supported the development of a high-caliber R&D team, enabling the successful completion of core material development.
2

2023 Pre-A Round

Investor: NHH Ventures

  • Accelerated CGM product development ahead of prototype completion.
  • Established advanced R&D and quality management systems.
3

2024 Pre-A+/A Series

Investors: Mission Palm Capital Inc., 3 Palm Capital Limited, NHH Ventures (continued investment)

  • Supported registration testing, clinical trials, and automated production line setup.
  • Expanded international markets and initiated multi-national licensing collaborations.
4

2025 Series B

In progress

  • Funding provided for global registration, capacity expansion, and market network development.
  • Accelerating the transition from technological breakthroughs to large-scale deployment.

Certifications